A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis

C J Fowler, J R Miller, M K Sharief, I F Hussain, V J Stecher, M Sweeney*

Objective: Identifying and effectively treating erectile dysfunction (ED) can result in an improvement of the quality of life (QoL) in men with multiple sclerosis (MS).

Methods: This randomised, double blind (DB), placebo controlled, flexible dose study with an open label extension (OLE) assessed efficacy, QoL, and safety of sildenafil citrate in men with MS and ED. Overall, 217 men received sildenafil (25–100 mg; n = 104) or placebo (n = 113) for 12 weeks. Efficacy was assessed by the International Index of Erectile Function (IIEF) questionnaire that includes questions on achieving (Q3) and maintaining (Q4) an erection as well as a global efficacy question (GEQ). QoL was also assessed.

Results: After 12 weeks, patients receiving sildenafil had higher mean scores for IIEF Q3 and Q4 compared with those receiving placebo (p < 0.0001), and 89% (92/103) reported improved erections compared with 24% (27/112) of patients receiving placebo (p < 0.0001). At the end of the OLE phase, 95% of men reported improved erections. Patients receiving placebo during the DB phase showed a nearly fourfold increase in improved erections (97% vs 26%). Men receiving sildenafil also showed improvements in five of the eight general QoL questions compared with men receiving placebo (p < 0.05). The total mean score for the QoL questionnaire improved by 43% for the sildenafil group versus 13% for the placebo group (p < 0.0001). Treatment related AEs were predominantly mild in nature, and no patient discontinued due to an AE.

Conclusion: Sildenafil treatment for ED in men with MS was effective and well tolerated, and resulted in significant improvements in both general and disease specific QoL variables.

Sexual dysfunction and especially erectile dysfunction (ED) is a common problem for men with multiple sclerosis (MS). Although several reports have now shown the incidence of ED in men with MS to be 50% to 75%, the frequency of the problem and its impact on the patient’s quality of life (QoL) have been underestimated in the past.

Sexual dysfunction is likely to occur at a time when the patient with MS is beginning to experience impaired mobility and other disabilities that interfere with aspects of social and occupational life, and it is thus likely to contribute to the depression and difficulties that accompany a progressively disabling disease. The dyadic relationship is particularly important in a disease in which one partner has to adjust to increasing physical dependency on the other, and restoration of erectile function may be of great significance to both partners. Therefore, identifying and effectively managing ED may result in an improvement in the QoL of patients with MS.

Formerly, ED in MS patients was thought to have a major psychological component, probably because under certain circumstances erections are preserved; however, it has since become clear that ED in patients with MS is commonly associated with neurogenic bladder dysfunction and that both disorders are the result of spinal cord involvement. Generally, with the onset of ED, men with MS continue to experience nocturnal erections or erections in response to genital stimulation, but these are often not sufficiently sustained for intercourse.

Sildenafil citrate is an effective and well tolerated treatment for ED of diverse causes, including spinal cord injury (SCI) and a peripheral site of action and enhances erectile function only after sexual stimulation. This randomised, placebo controlled study evaluated the efficacy and safety of sildenafil in men with ED and concomitant MS in addition to evaluating changes in their QoL following sildenafil treatment.

METHODS

Patients

The inclusion criteria for enrolement required that men be at least 18 years of age with a documented diagnosis of ED of greater than 6 months duration and be in a stable relationship with a woman for at least 6 months. Patients were also required to have a diagnosis by a neurologist of clinically definite MS of at least 1 year’s duration, based on standard clinical or investigational criteria; however, an omission not recognised at the time of this study was that no information on the type of MS was collected. In addition, patients were required to have a stable residual disability level of 2 to 6 inclusive on the Kurtzke Extended Disability Status Scale (EDSS), that is, they were ambulatory patients. All patients provided written informed consent.

Men were excluded from enrolment if they had genital anatomical deformities that significantly impaired erections or major haematological, renal, or hepatic abnormalities. Other exclusion criteria were the coexistence of other sexual disorders considered to be the primary diagnosis, an uncontrolled major psychiatric disorder, or significant cardiovascular disease (stroke or myocardial infarction within the previous 6 months; sitting blood pressure <90/50 mm Hg or >180/110 mm Hg). Patients with a known history of retinitis pigmentosa or who were taking nitrates, nitric oxide donors, and other drugs known to cause ED were also excluded.

Abbreviations: AE, adverse event; DB, double blind; ED, erectile dysfunction; EDSS, Extended Disability Status Scale; GEQ, global efficacy question; IIEF, International Index of Erectile Function; MS, multiple sclerosis; OLE, open label extension; QoL, quality of life; SCI, spinal cord injury
or who had used corticosteroids for the treatment of MS within the previous 2 months were not allowed to enter the study. Termination of other medications or therapies for ED was required.

Protocol and participant flow
This study was conducted between 1997 and 1999 at 20 sites (11 in the United States and nine in Europe) and had a 16 week, randomised, double blind (DB), placebo controlled, flexible dose design (fig 1). It was outpatient based and had a 4 week run in phase (week -4 to week 0), during which time baseline data on sexual function were collected. This was followed by a 12 week DB phase of treatment with sildenafil or placebo (week 0 to week 12). The 50 mg starting dose of sildenafil or matching placebo could be adjusted to 100 or 25 mg based on therapeutic response and tolerability. Patients were instructed to take sildenafil or placebo as required approximately 1 h before sexual activity, with a maximum dosing frequency of once daily. The DB treatment period was followed by an open label extension (OLE) phase. Men who had completed the DB phase or who had discontinued treatment due to lack of efficacy or non-treatment related adverse events (AEs) and for whom there were no safety or compliance concerns were eligible to enter the OLE phase, which lasted a minimum of 24 weeks up to a maximum of 48 weeks or until sildenafil became commercially available in the study country, whichever occurred first.

Randomisation and blinding
A randomisation list was generated using random permuted blocks through a computer algorithm and a pseudorandom number generator. The list indicated, for each bottle number, the drug assigned to the corresponding study medication bottle. The patient was assigned a screening number at visit one (screening) and, if eligible for participation, was then assigned a randomisation number at visit two (baseline). The investigator was provided a scaled copy of the randomisation codes and was instructed to break the treatment code only in the event of an emergency. Active treatment and corresponding placebo tablets were identical in packaging and appearance.

Efficacy and safety assessments
During the DB phase, the primary efficacy variables were responses to questions “When you attempted sexual intercourse, how often were you able to penetrate your partner?” (Q3) and “When you attempted sexual intercourse, how often were you able to maintain your erection after you had penetrated your partner?” (Q4) of the 15 item International Index of Erectile Function (IIEF). The IIEF is a validated questionnaire that has been used for the clinical assessment of ED. Each question of the IIEF is scored on a categorical scale of 1 (“almost never/never”) to 5 (“almost always/always”), with a score of 0 indicating “did not attempt sexual intercourse”. Secondary efficacy variables were responses to three global efficacy questions (GEQs): GEQ1: “Compared to having no treatment at all for your erection problem, has the medication you have been taking over the past 4 weeks improved your erections?” and GEQ2: “If yes, has the
improvement in your erections allowed you to engage in satisfactory sexual activity?". GEQ3 asked: "When you took a dose of study drug and had sexual stimulation, how often did you get an erection that allowed you to engage in satisfactory sexual activity?". GEQ3 was scored the same as the IIEF.

Additional secondary efficacy measures were analyses of IIEF domains, for example, orgasmic function (Q9: "When you had sexual stimulation or intercourse, how often did you ejaculate?" and Q10: "When you had sexual stimulation or intercourse, how often did you have the feeling of orgasm?") and sexual desire (Q11: "Over the past 4 weeks, how often have you felt sexual desire?" and Q12: "Over the past 4 weeks, how would you rate your level of sexual desire?"). AEs were recorded throughout the study. The DB end point efficacy assessment served as baseline for the OLE phase. At the final OLE visit, a limited assessment of efficacy was made based on responses to the three GEQs.

Quality of life assessments
Two instruments were used to assess QoL. The Life Satisfaction Checklist is an eight item general QoL questionnaire, with questions on the patient's satisfaction with life as a whole, sexual life, partnership relation, family life, social contacts, and leisure, vocational, and financial situations. The Erection Distress Scale is a disease specific instrument with five questions on the patient's concerns with his erection problems. These were: "Were you frustrated by your erection problems?", "Did you feel weighed down by your erection problems?", "Did you feel despair over your erection problems?", "Were you discouraged by your erection problems?", and "Were your erection problems a worry in your life?". Responses to each question of the Life Satisfaction Checklist and the Erection Distress Scale were scored from 1 (none of the time) to 6 (all of the time).

Analyses
Calculations were performed to determine the sample size needed to detect a statistical difference in the mean end point response for sildenafil (combined 25, 50, and 100 mg dose groups) versus placebo. Based upon a difference of 1.33 in mean scores and assuming a common standard deviation for groups using an approximation (two sided, t = 0.05) to the test comparing two means for normally distributed responses. Assuming an overall drop out rate of 25%, a 1:1 randomisation ratio of sildenafil to placebo, sufficient power to be able to conduct the primary analysis of efficacy, analysis of covariance, including terms for treatment group, centre, baseline value for efficacy variables, and other covariates as required, 250 patients, 125 in each arm, were to be randomised to study drug; in total, 218 patients were randomised.

Intent-to-treat analyses were performed on all efficacy and QoL variables, and included all patients with at least one assessment after randomisation who had taken at least one dose of study drug. To be eligible for inclusion in safety analyses, patients must have taken at least one dose of study drug. Statistical analysis of responses to IIEF Q3 and Q4 and GEQ3 was performed for each question using analysis of covariance. Statistical analysis of responses to GEQ1 and GEQ2 (yes/no) was performed for each question using a logistic regression model.

The mean frequency of responses to each question of the Life Satisfaction Checklist and to the five questions of the Erection Distress Scale for each treatment was calculated and expressed as the least squares mean ± standard error (SE). Each question was fitted with an analysis of covariance model, which included terms for treatment group, centre, patient age, baseline score, ED duration, baseline ED severity, and smoking status. All statistical tests were two sided and performed at the 5% significance level.

RESULTS
Efficacy during the double blind phase
A total of 217 men (mean age: 46 years; mean duration of ED: 5.7 years; mean duration of MS: 10.4 years) from 20 sites in the United States and Europe received treatment with sildenafil (n = 104) or placebo (n = 113) for 12 weeks. The patients in the two treatment groups had similar demographic characteristics with respect to age, duration of ED, duration of MS, and EDSS score (table 1), but men in the placebo group reported more frequent use of antihypertensive agents and less use of corticosteroids compared with the treatment group. At the end of the 12 week period, almost two thirds of men (64%) receiving sildenafil were taking the 100 mg dose, compared with 32% on the 50 mg dose, and 4% on the 25 mg dose. In the placebo group, 96% of men were taking the 100 mg dose, and 4% were taking the 50 mg dose.

The ability to achieve erections (IIEF Q3) and the ability to maintain erections (IIEF Q4) were improved in patients with MS who received sildenafil compared with those who received placebo (p < 0.0001; fig 2). When questions from the IIEF were analysed by domain, men taking sildenafil demonstrated a greater than fivefold improvement in orgasmic function (Q9, 10; p < 0.0001) and greater than fourfold improvement in sexual desire (Q11, 12; p = 0.0002) from baseline, compared with patients receiving placebo (fig 3).

Improvements in erections (GEQ1) were reported by 90% (95% CI: 82 to 94) of patients in the sildenafil group compared with 24% (95% CI: 17 to 33) of those in the placebo group (p < 0.0001; fig 4). In those patients with improved erections after sildenafil treatment (sildenafil responders), 92% (95% CI: 82 to 96) reported an improvement in the ability to have satisfactory sexual activity (GEQ2; fig 4). Patients taking sildenafil had a greater mean score for the frequency of erections that allowed satisfactory sexual activity (GEQ3, 4.0) compared with patients taking placebo (2.0; p < 0.0001).

Table 1 Demographics of treated patients

<table>
<thead>
<tr>
<th>Table 1 Demographics of treated patients</th>
<th>Placebo (n = 113)</th>
<th>Sildenafil (n = 104)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (range), years</td>
<td>47 (23–65)</td>
<td>45 (26–73)</td>
</tr>
<tr>
<td>Mean duration of ED, years</td>
<td>6.1</td>
<td>5.2</td>
</tr>
<tr>
<td>Mean duration of MS, years</td>
<td>10.1</td>
<td>10.7</td>
</tr>
<tr>
<td>Mean EDSS score (range)*</td>
<td>4.06 (1–5–6)</td>
<td>3.97 (1–6)</td>
</tr>
<tr>
<td>Concomitant medications, %†</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Analgesics</td>
<td>16.8</td>
<td>21.2</td>
</tr>
<tr>
<td>Antibacterials</td>
<td>13.3</td>
<td>13.3</td>
</tr>
<tr>
<td>Antidepressants</td>
<td>21.2</td>
<td>17.3</td>
</tr>
<tr>
<td>Antiepileptics</td>
<td>11.5</td>
<td>15.4</td>
</tr>
<tr>
<td>Antihypertensives</td>
<td>20.4</td>
<td>12.5</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>8.8</td>
<td>21.2</td>
</tr>
<tr>
<td>Drugs affecting immune response</td>
<td>22.5</td>
<td>28.8</td>
</tr>
<tr>
<td>Muscle relaxants/antispastic agents</td>
<td>27.4</td>
<td>29.8</td>
</tr>
<tr>
<td>Drugs for rheumatic diseases</td>
<td>22.1</td>
<td>16.3</td>
</tr>
<tr>
<td>Vitamins</td>
<td>19.5</td>
<td>15.4</td>
</tr>
</tbody>
</table>

*EDSS (Extended Disability Status Scale) scores available for 89 men (placebo) and 83 men (sildenafil); tused by >10% of patients.
Sildenafil citrate for erectile dysfunction

Figure 2 Mean scores (± SE) for IIEF Q3 (achieving erections) and Q4 (maintaining erections) are shown at baseline (grey bars) and with placebo (white bars) and sildenafil use (black bars). *p<0.0001 versus placebo. IIEF, International Index of Erectile Function.

Efficacy during the open label extension phase

Overall, 206 men (placebo: n = 106; sildenafil: n = 100) entered and 180 patients completed the 48 week OLE phase. At the end of the OLE phase, efficacy of sildenafil was sustained, with 95% of men reporting improved erections as determined by GEQ1. Of those patients, 95% also reported improved sexual activity (GEQ2). Patients who had received placebo during the DB phase showed a nearly fourfold increase in improved erections at the end of the OLE phase (97% vs 26%). An improvement in the ability to have successful sexual activity (GEQ2) was reported by men from both the DB placebo (96% vs 73%) and the sildenafil groups (94% vs 89%). However, because only patients who responded “yes” to GEQ1 were included here, these percentages are based on fewer patients from the DB placebo group (n = 26) than from the sildenafil group (n = 81) answering the GEQ2. At the end of the OLE phase, for patients who received DB placebo, the frequency of erections more than doubled (mean score: 4.35 and 1.98) and was similar to the frequency observed in men who received DB sildenafil (mean score: 4.26).

Quality of life

At the end of treatment, men with ED and MS who received sildenafil showed significant improvements in five of the eight variables of the general QoL questionnaire (Life Satisfaction Checklist) compared with those who received placebo (fig 5). The QoL variables that demonstrated an improvement from baseline in patients receiving sildenafil were satisfaction with life as a whole (13% sildenafil v 3.2% placebo; p = 0.001), sexual life (86% sildenafil v 22% placebo; p < 0.001), partnership relation (11% sildenafil v 2.3% placebo; p = 0.001), family life (7.5% sildenafil v 1.0% placebo; p = 0.003), and social contacts (3.5% sildenafil v 1.7% placebo; p = 0.03). The change in mean scores between the two treatment groups was not significantly different for satisfaction with leisure, vocational, or financial situation. The total mean score for the disease specific Erection Distress Scale increased 43% from baseline for the sildenafil group compared with 13% for the placebo group (p<0.0001).

Safety during the double blind phase

The most common AEs related to the study drug, which were predominantly mild to moderate in nature, are listed in table 2. Serious AEs were reported by three patients in the sildenafil group (urinary tract infection, worsening MS, exacerbation of MS) and three patients in the placebo group (weakness (probable worsening of MS), bone disorder, myocardial infarction). None of these events were considered by the investigator to be related to treatment. A total of 102 patients (98%) in the sildenafil group completed the study compared with 88 patients (78%) in the placebo group (table 2). No patient in the sildenafil group discontinued treatment because of an AE.

Figure 3 Improvements in the mean scores of two IIEF domains, orgasmic function and sexual desire, from baseline with placebo (white bars) or sildenafil treatment (black bars). *p<0.0001; †p=0.0002 versus placebo. IIEF, International Index of Erectile Function.

Figure 4 Percentage of patients reporting improvements in erections (GEQ1) with placebo (white bar) and sildenafil (black bar). The ability to have satisfactory sexual activity (GEQ2) is reported in those patients that responded to sildenafil (grey bar). Values represent estimated percentages calculated from logistic regression, adjusting for the model covariates. *p<0.0001 versus placebo. GEQ, global efficacy question.

Figure 5 Quality of life variables that improved with sildenafil treatment (black bars) compared with placebo (white bars). *p<0.05.
Erection until orgasm is achieved. function, with men feeling good about their ability to resume thoughts to happen secondary to improvements in erectile pharmacological mechanism of sildenafil is not expected to affect desire and orgasmic function, both domains showed an issue about patients being unblinded and introducing bias when answering subjective questionnaires. However, this is a potential issue in many clinical trials and the incidence of AEs related to sildenafil treatment in this study was comparable to that in other trials, for example, in patients with diabetes, depression, or SCI (range, 31–40%). Efficacy of sildenafil is comparable in men with ED and concomitant MS (current study) or SCI. The ability to achieve an erection (IIEF Q3) was improved 1.6-fold in MS patients and 1.8-fold in SCI patients; whereas the ability to maintain an erection (IIEF Q4) improved 1.9-fold in MS patients and 2.1-fold in SCI patients. From the GEQ, the percentage of MS patients reporting improved erections was 90% for sildenafil users compared with 24% for placebo users; the percentage of SCI patients reporting improved erections was 75% for sildenafil users compared with 7% of placebo users. These data demonstrate that patients with ED due to spinal disease respond well to treatment with sildenafil. The results are comparable to or better than a population of patients with ED of mixed etiology (72–79%) and markedly higher than in patients with diabetes mellitus (48–72%), whose poorly preserved vasculature might be the main reason for low efficacy. Interestingly, there appears to be a greater efficacy of sildenafil in patients with MS than in patients with diabetes, since 64% of men with MS preferred the 100 mg dose, compared with 75% of men with diabetes choosing that dose.

Moreover, greater efficacy in patients with MS may be due to the fact that sildenafil acts peripherally, and although psychogenically driven erections are likely to have been impaired by spinal cord disease, reflexogenic responses, subserved by sacral segmental pathways, are still intact. The average age of patients in this study is relatively young and with healthy peripheral neurovasculature a good erectile response is obtained by reflex mechanisms and what psychogenic responsiveness remains available.

Sildenafil was well tolerated in this study, as the majority of AEs reported during both phases were mild to moderate in severity and non-serious. AEs were those known to be associated with the mechanism of action of sildenafil, such as headache, vasodilation, and dyspepsia.

**CONTRIBUTORS**

The following clinical investigators contributed to this study:

Dr Hans Jacob Hansen, Århus, Denmark; Dr Andreo Larsen, Helsinki, Finland; Dr Ragnar Stien, Moelv, Norway; Dr Morten Andersen, Moelv, Norway; Dr Sten Fredriksen, Huddinge, Sweden; Professor Clare Fowler, London, UK; Dr Mohammed K. Sharief, London, UK; Dr Jackie Palace, London, UK; Dr Ronald Murray, Englewood, CO, USA; Dr Douglas Jeffery, Winston-Salem, NC, USA; Dr Michael Kaufman, Charlotte, NC, USA; Dr Mary Ann Picone, Teaneck, NJ, USA; Dr Iqbal Hussain, London, UK; Dr Andrew Goodman, Rochester, NY, USA; Dr Lawrence Jacobs, Buffalo, NY, USA; Dr Aaron Miller, Brooklyn, NY, USA; Dr James Miller, New York, NY, USA; Dr Robert Salani, New York, NY, USA.

Authors’ affiliations

C J Fowler, Department of Uro-Neurology, The National Hospital for Neurology and Neurosurgery, Mailbox 71, Queen Square, London WC1N 3BG, UK

J R Miller, The Neurologic Institute, 710 W. 168th Street, New York, NY 1003, USA

M K Sharief, Guy’s and St Thomas’ Hospital, London, UK

I F Hussain, V J Stecher, M Sweeney, Pfizer Inc., New York, NY, USA

This study was funded by Pfizer Inc.

Competing interests: C Fowler has been reimbursed by Pfizer Inc, for speaking at and attending conferences and has also received an

---

**Table 2 Treatment emergent AEs**

<table>
<thead>
<tr>
<th></th>
<th>DB phase, % of patients</th>
<th>OLE phase, % of patients</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n = 206)</td>
<td>Sildenafil (n = 206)</td>
</tr>
<tr>
<td>Patients with AEs of all causalities</td>
<td>46.3</td>
<td>73</td>
</tr>
<tr>
<td>Patients with treatment related AEs</td>
<td>6.2</td>
<td>42.3</td>
</tr>
<tr>
<td>Patients with serious AEs</td>
<td>2.7</td>
<td>2.9</td>
</tr>
<tr>
<td>Patients with severe AEs</td>
<td>3.5</td>
<td>9.6</td>
</tr>
<tr>
<td>Patients discontinued due to AEs</td>
<td>0.9</td>
<td>0</td>
</tr>
</tbody>
</table>

Most common AEs, all causality *(treatment related)*

<table>
<thead>
<tr>
<th>AEs</th>
<th>Placebo (n = 206)</th>
<th>Sildenafil (n = 206)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>7 (4)</td>
<td>27 (21)</td>
</tr>
<tr>
<td>Flushing</td>
<td>2 (2)</td>
<td>13 (13)</td>
</tr>
<tr>
<td>Weakness‡</td>
<td>1 (0)</td>
<td>6 (0)</td>
</tr>
<tr>
<td>MS relapse</td>
<td>2 (0)</td>
<td>7 (0)</td>
</tr>
<tr>
<td>Rhinitis</td>
<td>1 (0)</td>
<td>6 (4)</td>
</tr>
<tr>
<td>Chromatopsia</td>
<td>0 (0)</td>
<td>4 (4)</td>
</tr>
<tr>
<td>Dyspepsia</td>
<td>0 (0)</td>
<td>6 (3)</td>
</tr>
</tbody>
</table>

*AEs occurring in >3% of patients of either treatment group; ‡may include MS relapse not specified as such.

AE, adverse event; DB, double blind; MS, multiple sclerosis; OLE, open label extension.

**DISCUSSION**

Sildenafil significantly improved erectile function and the ability to engage in satisfactory sexual activity in men with ED due to MS. Treatment with sildenafil was well tolerated, with 98% of the patients completing the study. Furthermore, oral sildenafil treatment resulted in significant improvements in both general and disease specific QoL variables, and the treatment therefore represents an important advance in the management of ED in this group of patients.

Although men participating in this study were ambulatory, indicative of their relatively mild spinal cord involvement (Kurtzke EDSS <6.0), one would expect sildenafil to be effective in improving erectile function in patients with more advanced disease as well; this has been demonstrated in men with complete spinal cord transection. 14 14 Although the pharmacological mechanism of sildenafil is not expected to affect desire and orgasmic function, both domains showed improvement in this current study. These improvements are thought to happen secondary to improvements in erectile function, with men feeling good about their ability to resume sexual activity and sildenafil enabling them to sustain an erection until orgasm is achieved.

During the DB phase, AEs associated with sildenafil use occurred more frequently than in the placebo group, raising the issue about patients being unblinded and introducing bias when answering subjective questionnaires. However, this is a potential issue in many clinical trials and the incidence of AEs related to sildenafil treatment in this study was comparable to that in other trials, for example, in patients with diabetes, depression, or SCI (range, 31–40%).

Efficacy of sildenafil is comparable in men with ED and concomitant MS (current study) or SCI. The ability to achieve an erection (IIEF Q3) was improved 1.6-fold in MS patients and 1.8-fold in SCI patients; whereas the ability to maintain an erection (IIEF Q4) improved 1.9-fold in MS patients and 2.1-fold in SCI patients. From the GEQ, the percentage of MS patients reporting improved erections was 90% for sildenafil users compared with 24% for placebo users; the percentage of SCI patients reporting improved erections was 75% for sildenafil users compared with 7% of placebo users. These data demonstrate that patients with ED due to spinal disease respond well to treatment with sildenafil. The results are comparable to or better than a population of patients with ED of mixed etiology (72–79%) and markedly higher than in patients with diabetes mellitus (48–72%), whose poorly preserved vasculature might be the main reason for low efficacy. Interestingly, there appears to be a greater efficacy of sildenafil in patients with MS than in patients with diabetes, since 64% of men with MS preferred the 100 mg dose, compared with 75% of men with diabetes choosing that dose.

Moreover, greater efficacy in patients with MS may be due to the fact that sildenafil acts peripherally, and although psychogenically driven erections are likely to have been impaired by spinal cord disease, reflexogenic responses, subserved by sacral segmental pathways, are still intact. The average age of patients in this study is relatively young and with healthy peripheral neurovasculature a good erectile response is obtained by reflex mechanisms and what psychogenic responsiveness remains available.

Sildenafil was well tolerated in this study, as the majority of AEs reported during both phases were mild to moderate in severity and non-serious. AEs were those known to be associated with the mechanism of action of sildenafil, such as headache, vasodilation, and dyspepsia.

**CONTRIBUTORS**

The following clinical investigators contributed to this study:

Dr Hans Jacob Hansen, Århus, Denmark; Dr Andreo Larsen, Helsinki, Finland; Dr Ragnar Stien, Moelv, Norway; Dr Morten Andersen, Moelv, Norway; Dr Sten Fredriksen, Huddinge, Sweden; Professor Clare Fowler, London, UK; Dr Mohammed K. Sharief, London, UK; Dr Jackie Palace, London, UK; Dr Ronald Murray, Englewood, CO, USA; Dr Douglas Jeffery, Winston-Salem, NC, USA; Dr Michael Kaufman, Charlotte, NC, USA; Dr Mary Ann Picone, Teaneck, NJ, USA; Dr Iqbal Hussain, London, UK; Dr Andrew Goodman, Rochester, NY, USA; Dr Lawrence Jacobs, Buffalo, NY, USA; Dr Aaron Miller, Brooklyn, NY, USA; Dr James Miller, New York, NY, USA; Dr Robert Salani, New York, NY, USA.
unrestricted research grant from Pfizer Inc. JR Miller received reimbursement from Pfizer Inc. for attending a symposium. MK Sharief received funds for research from Pfizer Inc. IF Hussain was employed as a research fellow at the National Hospital for Neurology and Neurosurgery, Queen Square, London during the time of the study but is currently an employee of Pfizer Inc. M Sweeney are currently employees of Pfizer Inc. at the time this manuscript was submitted. VJ Stecher and M Sweeney are currently employees of Pfizer Inc.

*Current address: CV Therapeutics, 3172 Porter Drive, Palo Alto, CA 94304, USA.

REFERENCES
